Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus NEUROLITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus NEUROLITE.
FLUORODOPA F18 vs NEUROLITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
NEUROLITE is a sodium channel blocker that stabilizes neuronal membranes and inhibits the release of excitatory neurotransmitters, thereby reducing neuronal excitability and seizure propagation.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
300 mg orally twice daily.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal half-life: 12-15 hours; steady-state reached in 2-3 days
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal: 70% unchanged; Biliary/Fecal: 15% as metabolites; 15% other
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical